Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):128–134. doi: 10.1097/QAI.0000000000001586

Table 2.

Adjusted RDS-weighted logistic regression models of selected characteristics with odds of seroconversion,1 uConnect

Characteristic Network Model PrEP Model

(n = 326) (n = 304)

OR 95% CI OR 95% CI
Recent network members 12.96** 5.69–29.50 - -
Long-term network members 0.74 0.14–3.82 - -
Total network members 1.22* 1.01–1.46 8.91** 4.53–17.52
HIV-negative network members - - 0.14** 0.07–0.26
PrEP users in network - - 0.44* 0.20–0.96
Condomless sex2
 Never Ref - Ref -
 ≥ 1 time - - 0.51 0.16–1.63
Employment
 >30 hours Ref - Ref -
 <30 hours 1.37 0.23–8.19 1.87 0.27–13.00
 Unemployed 3.25 0.76–16.38 5.27* 1.19–23.41
Have health coverage
 No Ref - Ref -
 Yes 4.15* 1.11–15.53 2.64 0.85–8.16
Current student
 No Ref - Ref -
 Yes 0.77 0.31–1.92 0.76 0.37–1.54
In a relationship2
 No Ref - Ref -
 Yes 0.79 0.24–2.65 0.76 0.25–2.36
Marijuana use3
 Never Ref - Ref -
 Intermittent 0.42 0.08–2.40 0.42 0.10–1.77
 Heavy 0.12* 0.02–0.72 0.08** 0.02–0.41
Other Substance Use4
 None Ref - Ref -
 ≥ One other substance 5.63* 1.44–22.02 4.96* 1.33–18.54

Abbreviations: OR = odds ratio; CI = confidence interval; PrEP = pre-exposure prophylaxis;

1

Defined as HIV seropositive with previous HIV seronegative in a prior wave.

2

In the past 12 months

3

Intermittent use is defined as less than and including weekly use; heavy use is defined as at least once daily.

4

Includes the use of ecstasy/molly/E, marijuana, cocaine/crack, heroin, psychedelics, methamphetamines, prescription drugs

*

p <0.05;

**

p <0.001